Neuberger Berman Group
ITCI

Neuberger Berman Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Neuberger Berman Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-318,782
Closed -$42.1M – 2137
2025
Q1 		$42.1M Buy
318,782
+230,395
+261% +$28.7M 0.04% 465
2024
Q4 		$7.38M Buy
88,387
+1,117
+1% +$91.8K 0.01% 868
2024
Q3 		$6.39M Sell
87,270
-9,044
-9% -$680K 0.01% 880
2024
Q2 		$6.6M Buy
96,314
+14,498
+18% +$1.01M 0.01% 848
2024
Q1 		$5.66M Sell
81,816
-29,886
-27% -$2.05M ﹤0.01% 895
2023
Q4 		$8M Buy
111,702
+105,458
+1,689% +$6.07M ﹤0.01% 963
2023
Q3 		$325K Buy
6,244
+378
+6% +$22K ﹤0.01% 1570
2023
Q2 		$371K Buy
5,866
+454
+8% +$28.3K ﹤0.01% 1530
2023
Q1 		$293K Buy
5,412
+1,152
+27% +$55.7K ﹤0.01% 1605
2022
Q4 		$225K Buy
+4,260
New +$213K ﹤0.01% 1672
2016
Q1 		– Sell
-7,500
Closed -$403K – 1534
2015
Q4 		$403K Buy
+7,500
New +$378K ﹤0.01% 1323

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Neuberger Berman Group's ITCI Position: Q2 2025 in Review

Neuberger Berman Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 318,782 shares — an estimated $42.1M sold.

Neuberger Berman Group first reported a position in ITCI in Q4 2015 and held it in 11 quarters. The position peaked at $42.1M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Neuberger Berman Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 318,782 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $42.1M.
  • Neuberger Berman Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2015 and held it in 11 quarters.
  • Neuberger Berman Group's Intra-Cellular Therapies Inc. position peaked at $42.1M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Neuberger Berman Group's 13F filing for Q2 2025, filed 13 Aug 2025.